ストックスクリーナーアプリを入手
15.97
2.36%
-0.3478
前日終値:
$16.32
開ける：
$16.29
24時間の取引高:
7,957
Relative Volume:
0.22
時価総額：
$29.23M
収益：
-
当期純損益:
$-4.85M
株価収益率:
-51.52
EPS:
-0.31
ネットキャッシュフロー:
$-3.95M
1週間 パフォーマンス:
+6.23%
1か月 パフォーマンス:
-16.53%
6か月 パフォーマンス:
+3.81%
1年 パフォーマンス:
+172.45%
1日の値動き範囲:
$15.46
$16.76
1週間の範囲:
$14.10
$17.39
52週間の値動き範囲:
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
CVKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
16.09 | 29.23M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.18 | 126.49B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.77 | 59.71B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.88 | 36.26B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.39 | 29.48B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.75 | 25.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 開始されました | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com
Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter
Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World
CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa
CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India
(CVKD) Trading Signals - Stock Traders Daily
Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World
Biondi becomes managing partner at Flagship - BioCentury
Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks
Clinical Trials News Live Feed - StockTitan
Cadrenal Therapeutics appoints new chief medical officer - MSN
Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - Stock Titan
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace
Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan
(CVKD) Investment Report - Stock Traders Daily
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therape Latest Stock News & Market Updates - StockTitan
Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - Stock Titan
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
1.19%
2.07%
大文字化:
|
ボリューム (24 時間):